6-amino-4-ooxohexanoic acid | 102073-96-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: 6-amino-4-ooxohexanoic acid
• 英文别名: 6-amino-4-oxo-hexanoic acid；6-Amino-4-oxo-hexansaeure；6-amino-4-oxohexanoic acid
• CAS: 102073-96-1
• 化学式: C₆H₁₁NO₃
• mdl: MFCD19203991
• 分子量: 145.158
• InChiKey: ASOARLMYRNQLIL-UHFFFAOYSA-N

物化性质

• 熔点：
  128-130 °C
• 沸点：
  322.5±22.0 °C(Predicted)
• 密度：
  1.180±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -3.9
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  80.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-amino-4-ooxohexanoic acid 生成 琥珀半醛
  参考文献：
  名称：

  Mechanism of inactivation of .gamma.-aminobutyric acid aminotransferase by 4-amino-5-hexynoic acid (.gamma.-ethynyl GABA)

  摘要：

  Gamma-Aminobutyric acid (GABA) aminotransferase is a pyridoxal phosphate (PLP) dependent enzyme that catalyzes the degradation of gamma-aminobutyric acid. The inactivation of GABA aminotransferase has been shown to be an important treatment for epilepsy. The mechanism of inactivation of GABA aminotransferase by gamma-ethynyl GABA, a mechanism-based inactivator of GABA aminotransferase that shows anticonvulsant activity in animal models, is investigated in this paper. Although it appears that azaallylic isomerization (the normal catalytic pathway for substrates) of the PLP-bound inactivator occurs (pathway a, Scheme VII), little or no inactivation of the enzyme results from that isomerization. Essentially all of the inactivation is derived from a propargylic isomerization (pathway b) to the allenamine bound PLP adduct 10, which undergoes nucleophilic attack at two different sites. It appears that an active site lysine residue reacts at the Schiff base to give the free enamine 18 (pathway c) or reacts at the allene to give the enzyme and cofactor bound enamine 12 (pathway d); possible attack by water (pathway e) would lead to metabolite 26. The enamine 18 does not become attached to the PLP (Scheme III, pathway a), but a small amount (5-10%) may become attached to the enzyme at a site other than at lysine (9, Scheme III, pathway b). Adduct 9 also could be derived from azaallylic isomerization of the inactivator-PLP Schiff base followed by conjugate addition to the acetylene by an active site nucleophile other than a lysine residue (Scheme I). Mostly 18 is released into solution to give 27 (Scheme VII). Adduct 12 is believed to be a transient intermediate that partitions between conversion to metabolite 26 (Scheme VII, pathway f) and conversion to a more stable isomer (13, pathway g). Upon denaturation, adduct 13 partitions equally (Scheme VIII) between release of metabolite 26 and the formation of another covalent adduct (17). Isolation and identification of the amine and nonamine metabolites produced during processing of gamma-ethynyl GABA showed that, on average, for every 13 molecules of gamma-ethynyl GABA that are turned over, 1.2 undergoes transamination (pathway a, Scheme VII), 2.6 are metabolized to 27 (pathways b and c), 8.2 are converted to 26 (pathways b, d, and f and/or pathways b and e), and 1.0 becomes attached to the enzyme, almost all, as 13 (pathways b, d, and g), but possibly 5-10% as 9 (X not-equal Lys) as discussed above.

  DOI：

  10.1021/ja00024a042
• 作为产物：
  描述：

  6-nitro-4-oxo-hexanoic acid 在 盐酸 、 tin(ll) chloride 作用下， 生成 6-amino-4-ooxohexanoic acid
  参考文献：
  名称：

  Boffa, Gazzetta Chimica Italiana, 1956, vol. 86, p. 646,651

  摘要：

  DOI：

文献信息

• Enzymatically responsive magnetic particles and their use
  申请人：BRANDEIS UNIVERSITY

  公开号：US10857243B2

  公开（公告）日：2020-12-08

  The invention relates to an enzymatically responsive product that includes an amino acid residue conjugated to a magnetic particle, wherein the amino acid residue is phosphorylated or sulfated or comprises an ester-moiety linked via peptide bond. Compositions containing the enzymatically responsive product, and the use thereof for separating distinct types of mammalian cells (e.g., cancer cells from normal cells), for treating a cancerous condition, and imaging cancer cells are also disclosed.

  本发明涉及一种酶反应产品，它包括与磁性微粒共轭的氨基酸残基，其中氨基酸残基被磷酸化或硫酸化，或包括通过肽键连接的酯基。本发明还公开了含有该酶反应产物的组合物及其在分离不同类型的哺乳动物细胞（如癌细胞与正常细胞）、治疗癌症和癌细胞成像方面的用途。
• Conjugates for targeting and clearing aggregates
  申请人：MedImmune Limited

  公开号：US11065336B2

  公开（公告）日：2021-07-20

  In some embodiments, the disclosure provides for a conjugate comprising: a) a peptide that competes with an Fc fragment of an IgG for binding to an Fc receptor; and b) a targeting moiety that targets molecular aggregates. In some embodiments, the disclosure provides for methods of using the conjugates for treating a disease or disorder associated with aggregate formation.

  在一些实施方案中，本公开提供了一种共轭物，该共轭物包含：a)与 IgG 的 Fc 片段竞争与 Fc 受体结合的多肽；和 b)靶向分子聚集体的靶向分子。在一些实施方案中，本公开提供了使用共轭物治疗与聚集体形成相关的疾病或紊乱的方法。
• Synthetic peptides, enzymatic formation of pericellular hydrogels/nanofibrils, and methods of use
  申请人：BRANDEIS UNIVERSITY

  公开号：US11155576B2

  公开（公告）日：2021-10-26

  Disclosed are peptides that contain up to about 35 amino acids, including a plurality of aromatic amino acid residues and either (i) an amino acid residue that is phosphorylated or sulfated, or (ii) an amino acid comprising an ester-moiety linked via peptide bond, or both (i) and (ii), wherein the peptide is capable of self-assembly to form nanofibrils in the presence of an enzyme that hydrolyzes the phosphate group, the sulfate group, or the ester-moiety. These peptides are enzymatically responsive hydrogelators, and they can be used to form pericellular hydrogels/nanofibrils upon exposure to target cells that secrete or express a surface bound ectoenzyme having hydrolase activity suitable to induce peptide gelation. These materials, and compositions containing the same, can be used for in vitro and in vivo cellular imaging, treating cancerous conditions, collecting a secretome from a cell upon which the pericellular hydrogels/nanofibrils form, and screening the collected secretome.

  已公开的多肽含有多达约 35 个氨基酸，包括多个芳香族氨基酸残基和 (i) 磷酸化或硫酸化的氨基酸残基，或 (ii) 包含通过肽键连接的酯基的氨基酸，或 (i) 和 (ii) 两者，其中多肽能够在水解磷酸基、硫酸基或酯基的酶存在下自组装形成纳米纤维。这些肽是酶反应性水凝胶剂，当暴露于分泌或表达具有水解酶活性的表面结合外切酶的靶细胞时，可形成细胞周水凝胶/纳米纤维。这些材料和含有这些材料的组合物可用于体外和体内细胞成像、治疗癌症、从形成细胞周水凝胶/纳米纤维的细胞中收集分泌物组，以及筛选所收集的分泌物组。
• Structure-based de novo design of ligands using a three-dimensional model of the insulin receptor
  作者：Christopher Tan、Lianhu Wei、F.Peter Ottensmeyer、Ira Goldfine、Betty A. Maddux、Cecil C. Yip、Robert A. Batey、Lakshmi P. Kotra

  DOI：10.1016/j.bmcl.2004.01.064

  日期：2004.3

  For the first time, a three-dimensional model of the insulin receptor is used in the de novo design of novel ligands that potentially mimic interactions of insulin at its receptor. Compound 4 competed with insulin as seen in autophosphorylation assays and inhibited up to 68% of IR autophosphorylation at 300 muM of 4 in 3T3IR cells induced by 1 nM insulin. This model provides a basis for the design of potent insulin receptor ligands. (C) 2004 Elsevier Ltd. All rights reserved.
• Moldenhauer et al., Justus Liebigs Annalen der Chemie, 1953, vol. 583, p. 37,49
  作者：Moldenhauer et al.

  DOI：——

  日期：——